Logotype for Autolus Therapeutics plc

Autolus Therapeutics (AUTL) Q4 2022 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Autolus Therapeutics plc

Q4 2022 earnings summary

9 Nov, 2026

Executive summary

  • Clinical-stage programmed T-cell therapy developer with no approved products or product sales; 2022 revenue came from intellectual-property licensing. Net loss widened to £117.4m from £102.3m.

  • Cash and cash equivalents were £316.3m at year-end; management assessed funding to last through 30 June 2024, including under modeled downside scenarios.

Financial highlights

  • License revenue rose to £5.3m from £1.1m, reflecting Moderna’s option exercise and the BMS license upfront payment.

  • R&D expense increased 17% to £112.6m from £96.1m; G&A rose to £28.2m from £23.5m.

  • Operating loss was £136.8m versus £116.1m; income tax benefit was £19.3m versus £16.2m.

  • Net loss was £117.4m versus £102.3m; basic and diluted loss per share was £1.24 versus £1.42.

Outlook and guidance

  • Significant expenses are expected to continue as candidates advance through development, regulatory review and potential commercialization; substantial additional funding will be needed.

  • Cash forecasts, including sensitivities for clinical delays, inflation and lower R&D tax credits, showed sufficient liquidity through 30 June 2024; headcount reductions and cost delays were identified as levers.

  • Profitability depends on successful development, approval and commercialization of candidates and revenue sufficient to support the cost base.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Autolus Therapeutics